Glycopeptide antibiotics have become the last bastion for the treatment of multidrug-resistant Gram-positive hospital pathogens, the two main ones being methicillin-resistant S. aureus and enterococci. However, in addition to the emergence of vancomycin resistance in enterococci, certain staphylococcal strains with low-level resistance to glycopeptides have increasingly been isolated from clinical specimens. This review focuses on mechanisms of resistance, epidemiology, control measures and therapeutic options for these staphylococci.
No takes yet. Share an insight, caveat, or question.
Hiramatsu et al. (1998) studied this question.